Tue, November 15, 2022

Judah Frommer Maintained (STOK) at Buy with Decreased Target to $38 on, Nov 15th, 2022

Judah Frommer of Credit Suisse, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Decreased Target from $50 to $38 on, Nov 15th, 2022.

Judah has made no other calls on STOK in the last 4 months.



There is 1 other peer that has a rating on STOK. Out of the 1 peers that are also analyzing STOK, 0 agree with Judah's Rating of Hold.



This is the rating of the analyst that currently disagrees with Judah


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $25 on, Monday, November 14th, 2022